Stockscreener 앱 받기
13.82
5.74%
0.75
전일 마감가:
$13.07
열려 있는:
$13.01
하루 거래량:
98,604
Relative Volume:
0.76
시가총액:
$117.74M
수익:
$153.73M
순이익/손실:
$-106.79M
주가수익비율:
-7.764
EPS:
-1.78
순현금흐름:
$-115.93M
1주 성능:
+13.00%
1개월 성능:
+40.88%
6개월 성능:
+82.61%
1년 성능:
-25.30%
1일 변동 폭
$12.59
$14.21
1주일 범위
$10.52
$14.21
52주 변동 폭
$5.231
$21.50
Sutro Biopharma Inc Stock (STRO) Company Profile
명칭
Sutro Biopharma Inc
전화
650-392-8412
주소
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
STRO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
13.82 | 111.35M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2025-03-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-05-08 | 개시 | BofA Securities | Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Buy |
| 2023-10-06 | 개시 | Oppenheimer | Outperform |
| 2023-03-21 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | 재개 | Wells Fargo | Overweight |
| 2021-06-18 | 개시 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-02 | 개시 | Jefferies | Buy |
| 2020-07-16 | 개시 | Wells Fargo | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-10-07 | 개시 | BTIG Research | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2019-04-29 | 개시 | H.C. Wainwright | Buy |
| 2018-10-22 | 개시 | JMP Securities | Mkt Outperform |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
| 2018-10-22 | 개시 | Wedbush | Outperform |
모두보기
Sutro Biopharma Inc 주식(STRO)의 최신 뉴스
Aug Decliners: Is Sutro Biopharma Inc stock a value trapQuarterly Portfolio Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Sutro Biopharma: Streamlined strategy and advanced ADC pipeline drive clinical progress and differentiation - TradingView — Track All Markets
Sutro Biopharma: Accelerated ADC pipeline and strategic focus drive clinical progress and financial stability - TradingView — Track All Markets
Stock Recap: Is Sutro Biopharma Inc a potential multi baggerBull Run & Weekly Stock Breakout Alerts - baoquankhu1.vn
Volume Summary: Can Sutro Biopharma Inc reach resistance levels soonJuly 2025 Price Swings & Weekly Market Pulse Alerts - baoquankhu1.vn
Merger Talk: Why is Sutro Biopharma Inc stock going downQuarterly Profit Report & Proven Capital Preservation Tips - baoquankhu1.vn
Short Squeeze: Will Sutro Biopharma Inc stock benefit from sector rotationPortfolio Risk Summary & Detailed Earnings Play Alerts - Bộ Nội Vụ
Why millennials buy Sutro Biopharma Inc. (S09) stockMarket Trend Report & Fast Exit and Entry Strategy Plans - Улправда
Is Sutro Biopharma Inc. stock supported by strong cash flowsJuly 2025 Analyst Calls & Capital Efficiency Focused Ideas - Улправда
Is Sutro Biopharma Inc. stock a buy for dividend growth2025 Bull vs Bear & Precise Buy Zone Identification - Улправда
Is Sutro Biopharma Inc. stock undervalued vs historical averagesProfit Target & Risk Controlled Daily Plans - Улправда
Will Sutro Biopharma Inc. stock benefit from sector rotationInflation Watch & Consistent Return Strategy Ideas - Улправда
How risky is Sutro Biopharma Inc. stock nowJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - ulpravda.ru
What momentum indicators show for Sutro Biopharma Inc. stockPortfolio Risk Summary & Free Safe Capital Growth Stock Tips - Улправда
Sutro Biopharma, Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 - Quiver Quantitative
Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Growth Report: What consensus target says about Sutro Biopharma Inc S09 stockQuarterly Trade Report & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts - Defense World
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Treasury Yields: Can Sutro Biopharma Inc stock beat analyst upgradesGlobal Markets & Growth Focused Entry Reports - moha.gov.vn
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 46% - simplywall.st
Sutro Biopharma (NASDAQ:STRO) Will Have To Spend Its Cash Wisely - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Held Back By Insufficient Growth Even After Shares Climb 46% - 富途牛牛
Sutro Biopharma Stock Pre-Market (+6.9%): Momentum From Analyst EPS Upgrade - Trefis
Sutro Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
FY2025 EPS Estimate for Sutro Biopharma Increased by Analyst - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 85.9% in December - MarketBeat
Sutro Biopharma (NASDAQ:STRO) Given New $10.00 Price Target at HC Wainwright - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Sutro Biopharma (NASDAQ:STRO) Stock - MarketBeat
STRO: HC Wainwright Raises Price Target by 400% Today | STRO Sto - GuruFocus
HC Wainwright & Co. Maintains Sutro Biopharma (STRO) Neutral Recommendation - Nasdaq
Is Sutro Biopharma Inc. stock a contrarian buyQuarterly Trade Summary & High Accuracy Investment Entry Signals - Улправда
How rising interest rates impact Sutro Biopharma Inc. stockJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - Улправда
Can Sutro Biopharma Inc. stock continue upward trendQuarterly Profit Report & Accurate Buy Signal Alerts - Улправда
Aug Rallies: Why Sutro Biopharma Inc stock is trending among retail tradersPortfolio Update Summary & Growth Oriented Trading Recommendations - moha.gov.vn
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com
Why Sutro Biopharma Inc. (S09) stock benefits from AI revolutionM&A Rumor & Risk Controlled Daily Plans - DonanımHaber
Is Sutro Biopharma Inc. stock cheap at current valuationQuarterly Risk Review & Free Technical Pattern Based Buy Signals - DonanımHaber
Bear Alert: Is Sutro Biopharma Inc. stock a contrarian buyPortfolio Return Summary & AI Powered Market Entry Ideas - ulpravda.ru
Is Sutro Biopharma Inc. (S09) stock ideal for retirement investorsWeekly Trend Summary & Stepwise Entry and Exit Trade Signals - Улправда
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price - Investing.com Australia
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Listing Compliance - TipRanks
Sutro Biopharma regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Compliance - TradingView — Track All Markets
[8-K] SUTRO BIOPHARMA, INC. Reports Material Event | STRO SEC FilingForm 8-K - Stock Titan
Free cash flow per share of Sutro Biopharma, Inc. – MUN:S090 - TradingView — Track All Markets
Sutro Biopharma regains Nasdaq compliance after reverse stock split - Investing.com
Sutro Biopharma Inc (STRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Sutro Biopharma Inc 주식 (STRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Oct 15 '25 |
Buy |
0.80 |
17,000 |
13,607 |
71,832 |
| Chow Gregory K. | CFO |
Oct 15 '25 |
Buy |
0.81 |
19,750 |
15,998 |
19,750 |
| Chung Jane | Chief Executive Officer |
Oct 15 '25 |
Buy |
0.80 |
12,500 |
10,011 |
122,850 |
| MATSUI CONNIE | Director |
Oct 15 '25 |
Buy |
0.80 |
50,000 |
39,950 |
50,000 |
| Pauling David | Chief Admin. Ofcr. & GC |
Oct 15 '25 |
Buy |
0.80 |
12,504 |
9,993 |
71,737 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Sep 18 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
68,249 |
| Leyman Barbara | Chief Business Officer |
Jul 08 '25 |
Option Exercise |
0.00 |
25,000 |
0 |
25,000 |
| Chung Jane | Chief Executive Officer |
Aug 09 '25 |
Option Exercise |
0.00 |
18,750 |
0 |
117,058 |
| ALBINI EDWARD C | CFO AND SECRETARY |
May 15 '25 |
Option Exercise |
0.00 |
44,719 |
0 |
176,800 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
May 01 '25 |
Option Exercise |
0.00 |
37,849 |
0 |
133,282 |
4.73%
0.92%
자본화:
|
볼륨(24시간):